In conclusion, our data, together with previous reports, served to demonstrate that, when compared with control levels, increased plasma GFAP, NfL and T-tau in COVID-19 patients in the acute phase of infection are indicative of CNS vulnerability. The gene discussed is MAPT; the disease is COVID-19.